
Development of the Venetoclax-Resistant AML Model
Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...
Continue Reading
Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...
Continue Reading
At DDC 2026, WuXi AppTec presented a poster showcasing our integrated discovery platform designed to accelerate the identification and validation...
Continue Reading
High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...
Continue Reading
Current weight-loss therapies primarily act on the gut–brain axis, often using incretin-based approaches such as GIP, GLP-1, and glucagon receptor...
Continue Reading
In recent years, peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages,...
Continue Reading
Looking for a solution to accelerate your drug discovery processes? WuXi AppTec’s integrated Direct-to-Biology (D2B) platform is a cost-effective and...
Continue Reading
AACR 2026 Posters | Sneak Peek The Annual Meeting of the American Association for Cancer Research (AACR) will be held...
Continue Reading
Accelerating SLE Drug Discovery: A Short-Term BM12-Induced Mouse Model for Efficient Drug Screening Systemic lupus erythematosus (SLE) is a chronic...
Continue Reading
From Undruggable to Actionable: Advanced Screening Methods for Better Drug Targets Introduction: Identifying a high-quality drug target is the cornerstone...
Continue Reading